Johnson & Johnson subsidiary Cordis Endovascular has received the European CE Mark for its Cypher Select sirolimus-eluting stent.
The stent received the CE Mark for use in the treatment of severe claudication and critical limb ischemia (CLI) of infrapopliteal lesions, according to the Warren, NJ-based firm.
By AuntMinnie.com staff writers
September 6, 2006
Related Reading
Cordis introduces Steer-It guidewire, August 29, 2006
Cordis builds Irish facility, July 25, 2006
Cordis acquires Ensure Medical, July 13, 2006
Cordis Cypher Select Plus nets CE Mark, June 22, 2006
J&J to appeal Boston Scientific stent ruling, June 16, 2006
Copyright © 2006 AuntMinnie.com